Sara Tolaney, SABCS 2022: Adjuvant paclitaxel and trastuzumab for node-negative HER2+ breast cancer

SABCS22: Sara Tolaney, MD, MPH | Dana-Farber Cancer InstituteПодробнее

5-year correlative analysis of ATEMPT: adjuvant T-DM1 vs paclitaxel+trastuzumab for stage I HER2+ BCПодробнее

Dr. Tolaney on the ATEMPT Trial for HER2+ Breast CancerПодробнее

Dr Sara M. Tolaney Discusses the Role of Adjuvant Therapy in HER2-Positive Breast CancerПодробнее

APT: adjuvant paclitaxel and trastuzumab for node-negative, HER2+ breast cancerПодробнее

Key data from the San Antonio Breast Cancer Symposium (SABCS) 2022Подробнее

Dr. Sara Tolaney on Adjuvant T-DM1 Vs Paclitaxel and Trastuzumab for Stage I HER2+ Breast CancerПодробнее

The San Antonio Breast Cancer Symposium (SABCS) 2022Подробнее

SABCS 2022 highlightsПодробнее

Mafalda Oliveira, SABCS 2022: Camizestrant vs fulvestrant for advanced ER+ HER2- breast cancerПодробнее

Dr. Burstein on the Results of the APT Trial for HER2+ Breast CancerПодробнее

San Antonio Breast Cancer Symposium 2022 highlightsПодробнее

Patient Perspectives on T-DM1 vs Paclitaxel/Trastuzumab for HER2+ Early Breast CancerПодробнее

Sara Tolaney MD, MPH shares results from the Phase 2 ATEMPT trial at SABCS 2019Подробнее

Dr. Tolaney on Deescalating Therapy in Stage I HER2+ Breast CancerПодробнее

Highlights from the San Antonio Breast Cancer Symposium 2022Подробнее

Dr. Melinda Telli | Sa Antonio Breast Cancer Symposium 2022 | Clinical Research WorkshopПодробнее

Highlights in HER2-low breast cancer at SABCS 2022Подробнее

Key takeaways from SABCS 2022Подробнее